Qutenza^®: a capsaicin 8% patch for the management of postherpetic neuralgia

References

• Treede R, Jensen T, Campbell J et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology70(18), 1630–1635 (2008).
   PubMed Web of Science ®Google Scholar
• Bennett GJ. Neuropathic pain: new insights, new interventions. Hosp. Pract.33, 95–114 (1998).
   PubMed Web of Science ®Google Scholar
• Gustorff B, Dorner T, Likar R et al. Prevalence of self-reported neuropathic pain and impact on quality of life: a prospective representative survey. Acta Anaesthesiol. Scand.52(1), 132–136 (2008).
   PubMed Web of Science ®Google Scholar
• Bouhassira D, Lanteri-Minet M, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain136(3), 380–387 (2008).
   PubMed Web of Science ®Google Scholar
• Rowbotham MC, Fields HL. The relationship of pain, allodynia and thermal sensation in post-herpetic neuralgia. Brain119(Pt 2), 347–354 (1996).
   PubMed Web of Science ®Google Scholar
• Attal N, Cruccu G, Baron R et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur. J. Neurol.17(9), 1113–e88 (2010).
   PubMed Web of Science ®Google Scholar
• Dworkin RH, O’Connor AB, Audette J et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin. Proc.85(3 Suppl.), S3–S14 (2010).
   PubMed Web of Science ®Google Scholar
• Moulin DE, Clark AJ, Gilron I et al. Pharmacological management of chronic neuropathic pain – consensus statement and guidelines from the Canadian Pain Society. Pain Res. Manag.12(1), 13–21 (2007).
   PubMed Web of Science ®Google Scholar
• Jackson KC. Pharmacotherapy for neuropathic pain. Pain Pract.6, 27–33 (2006).
   PubMedGoogle Scholar
• Backonja M, Irving G, Argoff CE. Rationale multidrug therapy in the treatment of neuropathic pain. Curr. Pain Headache Rep.10, 34–38 (2006).
   PubMedGoogle Scholar
• Field MJ, Hughes J, Singh L. Further evidence for the role of the α(2)δ subunit of voltage dependent calcium channels in models of neuropathic pain. Br. J. Pharmacol.131, 282–286 (2000).
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Corbin AE, Young JP et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology60, 1274–1288 (2003).
   PubMed Web of Science ®Google Scholar
• Rice AS, Maton S. Gabapentin in postherpetic neuralgia: a randomized, double blind, placebo controlled study. Pain94, 215–224 (2001).
   PubMed Web of Science ®Google Scholar
• Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA280, 1837–1863 (1998).
   PubMed Web of Science ®Google Scholar
• Rice A, Maton S. Gabapentin in postherpetic neuralgia: a randomized, double blind, placebo controlled study. Pain94(2), 215–224 (2001).
   PubMed Web of Science ®Google Scholar
• van Seventer R, Feister H, Young J, Stoker M, Versavel M, Rigaudy L. Efficacy and tolerability of twice daily gabapentin for treating pain and related sleep interference in post herpetic neuralgia: a 13 week randomized trial. Curr. Med. Res. Opin.22, 375–384 (2006).
   PubMed Web of Science ®Google Scholar
• Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain65, 39–44 (1996).
   PubMed Web of Science ®Google Scholar
• Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain80, 533–538 (1999).
   PubMed Web of Science ®Google Scholar
• Watson C, Evans R, Reed K, Goldsmith L, Warsh J. Amitriptylin versus placebo in postherpetic neuralgia. Neurology32(6), 671–673 (1982).
   PubMed Web of Science ®Google Scholar
• Max MB, Schafer SC, Culnane M, Smoller B, Dubner R, Gracely RH. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology38(9), 1427–1432 (1988).
   PubMed Web of Science ®Google Scholar
• Graff-Radford S, Shaw L, Naliboff N. Amitriptylin and fluphenazim in treatment of postherpetic neuralgia. Clin. J. Pain16(3), 188–192 (2000).
   PubMed Web of Science ®Google Scholar
• Max M, Schafer S, Gaughan A, Smoller B, Gracely R, Dubner R. Desipramine relieves postherpetic neuralgia. Clin. Pharmacol. Ther.47(3), 305–312 (1990).
   PubMed Web of Science ®Google Scholar
• Raja SN, Haythornthwaite JA, Pappagallo M et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology59(7), 1015–1021 (2002).
   PubMed Web of Science ®Google Scholar
• Raja S, Haythornthwaite J, Pappagallo M et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology59(7), 1015–1021 (2002).
   PubMed Web of Science ®Google Scholar
• Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology50(6), 1837–1841 (1998).
   PubMed Web of Science ®Google Scholar
• Harati Y, Gooch C, Swenson M et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology50(6), 1842–1846 (1998).
   PubMed Web of Science ®Google Scholar
• Sindup SH, Andersen G, Madsen C, Smith T, Brosen K, Jensen T. Tramadol relieves pain and allodynia in polyneuropathy, a randomized, double-blind controlled trial. Pain83(1), 85–90 (1999).
   PubMed Web of Science ®Google Scholar
• Szallasi A, Blumberg PM. Vanilloid (capsaicin) receptors and mechanisms. Pharmacol. Rev.51, 159–211 (1999).
   PubMed Web of Science ®Google Scholar
• Jancso N, Jancso A. Desensitization of sensory nerve endings. Kiserl. Orvostud.2(Suppl.), 15 (1949).
   Google Scholar
• Derry S, Lloyd R, Moore R, McGuay H. ‘Topical Capsaisin for chronic neuropathic pain in adults’. Cochrane Database Syst. Rev. (4), CD007393 (2009).
   Google Scholar
• Zhang WY, Li Wan Po A. The effectiveness of topically applied capsaicin. A meta-analysis. Eur. J. Clin. Pharmacol.46(6), 517–522 (1994).
   PubMed Web of Science ®Google Scholar
• Johnson W. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin. Int. J. Toxicol.26(Suppl. 1), 3–106 (2007).
   Web of Science ®Google Scholar
• Surh Y-J, Lee SS. Capsaicin in hot chili pepper: carcinogen, co-carcinogen, or anticarcinogen? Food Chem. Toxicol.34, 313–316 (1996).
   PubMed Web of Science ®Google Scholar
• Caterina MJ, Schumacher M, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature389, 816–824 (1997).
   PubMed Web of Science ®Google Scholar
• Spicarova D, Palecek J. The role of spinal cord vanilloid (TRPV1) receptors in pain modulation. Physiol. Res.57(Suppl. 3), S69–S77 (2008).
   Google Scholar
• Nolano M, Simone DA, Wendelschafer-Crabb G, Johnson T, Hazen E, Kennedy WR. Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain81, 135–145 (1999).
   PubMed Web of Science ®Google Scholar
• McMahon SB. The consequence of long-term topical capsaicin application in the rat. Pain44, 301–310 (1991).
   PubMed Web of Science ®Google Scholar
• Kasting GB, Francis WR, Bowman LA, Kinnett GO. Percutaneous asborption of vanilloids: in vivo and in vitro studies. J. Pharm. Sci.86, 142–146 (1997).
   PubMed Web of Science ®Google Scholar
• Fang J-Y, Wu P-C, Huang Y-B, Tsai Y-H. In vivo permeation study of capsaicin and its synthetic derivatives from ointment bases using various skin types. Int. J. Pharm.126, 119–128 (1995).
   Web of Science ®Google Scholar
• Fang J-Y, Wu P-C, Huang SM, Tsai Y-H. In vivo percutaneous absorption of capsaicin, nonivamide and sodium nonivamide acetate from ointment bases: skin erythema test and non-invasive surface recovery technique in humans. Int. J. Pharm.131, 143–151 (1996).
   Web of Science ®Google Scholar
• Fang J-Y, Wu P-C, Huang SM, Tsai Y-H. In vivo percutaneous absorption of capsaicin, nonivamide and sodium nonivamide acetate ointment bases: pharmacokinetics analysis in rabbits. Int. J. Pharm.128, 169–177 (1996).
   Google Scholar
• Babbar S, Marier JF, Mouksassi MS et al. Pharmacokinetic analysis of capsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neuropathic pain. Ther. Drug Monit.31(4), 502–510 (2009).
   PubMed Web of Science ®Google Scholar
• Malmberg AB, Mizisin AP, Calcutt NA, von Stein T, Robbins WR, Bley KR. Reduced heat sensitivity and epidermal nerve fiber immunostaining following single applications of a high-concentration capsaicin patch. Pain111(3), 360–367 (2004).
   PubMed Web of Science ®Google Scholar
• Kennedy WR, Vanhove GF, Lu SP et al. A randomized, controlled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers. J. Pain11(6), 579–587 (2010).
   PubMed Web of Science ®Google Scholar
• Backonja MM, Malan TP, Vanhove GF, Tobias JK. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension. Pain Med.11(4), 600–608 (2010).
   PubMed Web of Science ®Google Scholar
• Webster LR, Malan TP, Tuchman MM, Mollen MD, Tobias J, Vanhove GF. A multicenter, randomized, double-blind, conrolled dose finding study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. J. Pain11(10), 972–982 (2010).
   PubMed Web of Science ®Google Scholar
• Webster LR, Tark M, Rauck R, Tobias JK, Vanhove GF. Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia. BMC Neurol.10, 92 (2010).
   PubMed Web of Science ®Google Scholar
• Backonja M, Wallace MS, Blonsky ER et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol.7(12), 1106–1112 (2008).
   PubMed Web of Science ®Google Scholar
• Backonja M, Dunteman E, Irving G et al. One 60-minute application of a high-concentration capsaicin patch (NGX-4010) significantly reduced pain for up to 3 months in patients with postherpetic neuralgia: results from a randomized, double-blind, controlled Phase 3 study. Neurology70(Suppl. 1), A162–A163 (2008).
   Google Scholar
• Yosipovitch G, Maibach H, Rowbotham MC. Effect of EMLA pre-treatment on capsaicin-induced burning and hyperalgesia. Acta Derm. Venereol.79, 118–121 (1999).
   PubMed Web of Science ®Google Scholar
• Ngom PI, Dubray C, Woda A, Dallel R. A human oral capsaicin pain model to assess topical anesthetic-analgesic drugs. Neurosci. Lett.316(3), 149–152 (2001).
   PubMed Web of Science ®Google Scholar
• Wallace M, Lam V, Schulteis G. Effect of lidocaine patch on thermal thresholds and experiments pain. J. Pain8(Suppl. 1), 790 (2007).
   Google Scholar
• Wallace MS, Abrams DI, Yaksh TL. Concentration-effect relations for intravenous lidocaine infusions in human volunteers: effect on acute sensory thresholds and capsaicin-evoked hyperpathia. Anesthesiology86, 1262–1272 (1997).
   PubMed Web of Science ®Google Scholar
• Petersen KL, Maloney A, Hoke F, Dahl JB, Rowbotham MC. A randomized study of the effect of oral lamotrigine and hydromorphone on pain and hyperalgesia following heat/capsaicin sensitization. J. Pain4(7), 400–406 (2003).
   PubMed Web of Science ®Google Scholar
• Dirks J, Fabricius P, Petersen KL, Rowbotham MC, Dahl JB. The effect of systemic lidocaine on pain and secondary hyperalgesia associated with the heat/capsaicin sensitization model in healthy volunteers. Anesth. Analg.9, 967–972 (2000).
   Google Scholar
• Wallace M, Quessy S, Schulteis G. Lack of effect of two oral sodium channel antagonists, lamotrigine and 4030W92, on intradermal capsaicin-induced hyperalgesia model. Pharmacol. Biochem. Behav.78, 349–355 (2004).
   PubMed Web of Science ®Google Scholar
• LaMotte RH, Lundberg LE, Torebjork E. Pain, hyperalgesia and activity in nociceptive C units in humans after intradermal injection of capsaicin. J. Physiol.448, 749–764 (1992).
   PubMed Web of Science ®Google Scholar
• Wallace MS, Ridgeway B, Leung A, Schulteis G, Yaksh TL. Concentration-effect relationships for intravenous alfentanil and ketamine infusions in human volunteers: effects upon acute thresholds and capsaicin-evoked hyperpathia. J. Clin. Pharmacol.42, 70–80 (2002).
   PubMed Web of Science ®Google Scholar
• Sethna NF, Liu M, Gracely R, Bennett GJ, Max MB. Analgesic and cognitive effects of intravenous ketamine-alfentanil combinations versus either drug alone after intradermal capsaicin in normal subjects. Anesth. Analg.86(6), 1250–1256 (1998).
   PubMed Web of Science ®Google Scholar
• Petersen KL, Jones B, Segredo V, Dahl JB, Rowbotham MC. Effect of remifentanil on pain and secondary hyperalgesia associated with the heat – capsaicin sensitization model in healthy volunteers. Anesthesiology94(1), 15–20 (2001).
   PubMed Web of Science ®Google Scholar
• Qutenza® capsaicin 8% patch. Package insert. NeurogesX, Inc., CA, USA.
   Google Scholar
• Simpson DA, Gazda S, Brown S et al. Long-term safety of NGX-4010, a high-concentration patch in patients with peripheral neuropathic pain. J. Pain Sympt. Manage.39(6), 1053–1064 (2010).
   PubMed Web of Science ®Google Scholar
• Galler J, Pozo MA, Rebollo I, Belmonte C. Effects of capsaicin on corneal wound-healing. Clin. Invest. Ophthalmol. Vis. Sci.31(10), 1968–1974 (1990).
   PubMed Web of Science ®Google Scholar
• Ko F, Diaz M, Smith P et al. Toxic effects of capsaicin on keratinocytes and fibroblasts. J. Burn Care Rehabil.19(5), 409–413 (1998).
   PubMedGoogle Scholar
• Watcher MA, Wheeland RG. The role of topical agents in the healing of full-thickness wounds. J. Dermatol. Surg. Oncol.15(11), 1188–1195 (1989).
   PubMedGoogle Scholar
• Webster LR, Peppin JF, Murphy FT, Tobias JK, Vanhove GF. Tolerability of NGX-4010 in conjunction with three topical anesthetic formulations for the treatment of neuropathic pain. Presented at: The American Academy of Pain Medicine 2010 Annual Meeting, San Antonio, TX, USA, February 3–6 (2010).
   Google Scholar
• Webster LR, Tran J, Wilson P et al. Tolerability of treatment with NGX-4010 in conjunction with pre-patch topical application of a lidocaine 2.5%/prilocaine 2.5% anesthetic cream. Presented at: The American Academy of Pain Medicine 2010 Annual Meeting, San Antonio, TX, USA, February 3–6 (2010).
   Google Scholar